Business briefs: GSK, DOJ, Sanofi, Flashpoint Medica

Share this article:

GlaxoSmithKline dismissed its SVP and head of R&D in Shanghai, Jingwu Zang, over fabricated data which was published in the scientific journal Nature. GSK has also placed three other employees on administrative leave pending a final review, and one other employee has resigned as a result of the allegations. The three-year-old paper in question examined the role of a protein called Interleukin-7 in treating autoimmune disorders.

The Justice Department agreed to stop trying to block the availability of over-the-counter Plan-B today. The New York Times reported that the Justice Department “appears to have concluded that it might its case with the appeals court and would have to decide whether to appeal to the Supreme Court,” an unlikely move which would cast the delicate issue and it's back-and-forth into the political limelight.

FDA approved Sanofi's Fluzone Quadrivalent. The new flu vaccine protects against four strains of the disease and is approved for use in children six months of age and older along with adolescents and adults. Fluzone Quadrivalent will see its first flu season in 2013.

Flashpoint Medica chief Charlene Prounis was selected by the Women's Venture Fund to receive the “Highest Leaf Award.” The annual award is given to women executives “who contribute significantly to their respective industries while assisting other women in developing the skills and resources for attaining their own business goals.”  The Highest Leaf Award will be presented to Prounis, who is CEO and managing partner of Flashpoint Medica, on Wednesday, June 12 at the Harvard Club in New York City.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.